Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV efgartigimod in adults with primary Sjögren's syndrome
NL-OMON53789Phase 2Active, not recruiting
- Sponsor
- IQVIA
- Start
- Dec 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Efgartigimod IV with Placebo (2 arms). Primary endpoint: CRESS responder rate at week 24. Started Dec 2022; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON53789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53789.